0001084201 – Page 35 – China Stock Advice

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Announces Management Changes -Chief Financial Officer Resigns - -Vice President of Sinovac Named Interim Chief Financial Officer BEIJING, August 5, 2011 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the resignation of Jacob Chik Keung Ho, its Chief Financial Officer, for personal reasons. The Company has initiated an executive search for] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD. August 5]

By info| 2016-03-24T01:47:04+00:00 August 8th, 2011|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2011-08-08, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces Management Changes -Chief Financial Officer Resigns

[Sinovac Announces Management Changes -Chief Financial Officer Resigns - -Vice President of Sinovac Named Interim Chief Financial Officer BEIJING, August 5, 2011 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the resignation of Jacob Chik Keung Ho, its Chief Financial Officer, for personal reasons. The Company has initiated an executive search for] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD. August 5]

By info| 2016-03-24T01:48:23+00:00 August 8th, 2011|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2011-08-08, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Holds 2011 Annual Shareholders Meeting Press Release

[Sinovac Holds 2011 Annual Shareholders Meeting Press Release Source: Sinovac Biotech Ltd. On Thursday July 14, 2011, 8:00 am EDT BEIJING, July 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time.] [Amendments to the By-Laws of the Company 1 The existing By-Laws of the Company (as last amended on March 31, 2006) shall be amended by adding a definition of “special resolution,” and replacing the definition of “ordinary resolution” and Section 7.8 as follows: “ORDINARY RESOLUTION SPECIAL RESOLUTION 7.8 Votes of Shareholders Subject to any rights or restrictions for the time] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]

By info| 2016-03-24T01:51:26+00:00 July 20th, 2011|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2011-07-20, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) – SVA News BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: The phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of] [Sinovac Commences Phase II Clinical Trial for EV71 Vaccine BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]

By info| 2016-03-24T01:52:28+00:00 July 20th, 2011|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2011-07-20, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Positive Phase I Clinical Trial Results

[Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) – SVA News BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: The phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of] [Sinovac Commences Phase II Clinical Trial for EV71 Vaccine BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]

By info| 2016-03-24T01:54:01+00:00 July 20th, 2011|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2011-07-20, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Holds 2011 Annual Shareholders Meeting Press Release Source: Sinovac Biotech Ltd. On Thursday July 14, 2011, 8:00 am EDT BEIJING, July 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time.] [Amendments to the By-Laws of the Company 1 The existing By-Laws of the Company (as last amended on March 31, 2006) shall be amended by adding a definition of “special resolution,” and replacing the definition of “ordinary resolution” and Section 7.8 as follows: “ORDINARY RESOLUTION SPECIAL RESOLUTION 7.8 Votes of Shareholders Subject to any rights or restrictions for the time] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]

By info| 2016-03-24T01:49:46+00:00 July 20th, 2011|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2011-07-20, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2011 Financial Results - Conference call scheduled for Friday, May 13, 2011 at 8:00 AM EDT – BEIJING, May 13, 2011 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011. First Quarter 2011 Financial] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x ¨ Form 20-F SINOVAC BIOTECH LTD.]

By info| 2016-03-24T01:55:10+00:00 July 11th, 2011|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2011-07-11, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited First Quarter 2011 Financial Results

[Sinovac Reports Unaudited First Quarter 2011 Financial Results - Conference call scheduled for Friday, May 13, 2011 at 8:00 AM EDT – BEIJING, May 13, 2011 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011. First Quarter 2011 Financial] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x ¨ Form 20-F SINOVAC BIOTECH LTD.]

By info| 2016-03-24T01:56:43+00:00 July 11th, 2011|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2011-07-11, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] SC 13D: SAIF Partners IV L.P. Andrew Y. Yan Director

[SAIF Partners IV L.P. Andrew Y. Yan Director of SAIF IV GP Capital Ltd., which is SAIF IV GP L.P. Andrew Y. Yan Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P. SAIF IV GP Capital Ltd. Andrew Y. Yan Director of SAIF IV GP Capital Ltd.] [CUSIP No. P8696W104 1 NAMES OF REPORTING PERSONS 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) o (a) þ (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) WC 5]

By info| 2016-03-24T01:58:55+00:00 May 31st, 2011|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2011-05-31, 2834, PHARMACEUTICAL PREPARATIONS, SC_13D, SVA|0 Comments

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report. 54,305,961 common shares as of December 31, 2010 o x o x x o o o] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Jacob Chik Keung Ho, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [Certification by the Chief Executive Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 13 v219311_ex13-1.htm] [Certification by the Chief Financial Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 14 v219311_ex13-2.htm] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S−8 No. 333−161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 22, 2011, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting]

By info| 2016-03-24T02:00:43+00:00 April 22nd, 2011|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 20-F, 2011-04-22, 2834, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments